Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1143 • 2018 ACR/ARHP Annual Meeting
Periodontal Disease Is Associated with an Increased Risk of Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Karn Wijarnpreecha² and Wisit Cheungpasitporn³, ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Internal medicine, Bassett medical center, cooperstown, NY, ³Medicine, University of Mississippi Medical center, Jackson, MS
Periodontal Disease is Associated with an Increased Risk of Ankylosing Spondylitis: A Systematic Review and Meta-analysisAbstractBackground/Purpose: The association between periodontal disease and rheumatoid arthritis is…
Abstract Number: 1638 • 2018 ACR/ARHP Annual Meeting
Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies
Louis Bessette¹, Majed Khraishi^2,3, Brandusa Florica⁴, Yatish Setty⁵, Michelle Teo⁶ and Valencia P. Remple⁷, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Grey Bruce Health Services, Owen Sound, ON, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷AbbVie Corporation, Montreal, QC, Canada
Background/Purpose: Extra-articular manifestations (EAMs) in rheumatic diseases have been previously found to negatively impact health outcomes including quality of life and work capacity. Even though…
Abstract Number: 2584 • 2018 ACR/ARHP Annual Meeting
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
Atul A. Deodhar¹, Corinne Miceli-Richard², Xenofon Baraliakos³, Helena Marzo-Ortega⁴, Dafna D Gladman⁵, Ruvie Martin⁶, Jorge Safi⁷, Brian Porter⁷ and Abhijit Shete⁸, ¹Oregon Health & Science University, Portland, OR, ²Rheumatology Department, Paris Descartes University, Paris, France, ³Ruhr-University Bochum, Herne, Germany, ⁴NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Uveitis, a common extra-articular manifestation of spondyloarthritis (SpA), has an estimated prevalence of 33.2% in patients with ankylosing spondylitis (AS), which increases with duration…
Abstract Number: 659 • 2018 ACR/ARHP Annual Meeting
Comparison of MRI and Conventional Radiography for Detection of Structural Changes Typical for Spa – Data from the Assessment of Spondyloarthritis International Society Cohort
Mikhail Protopopov¹, Denis Poddubnyy^2,3, Fabian Proft¹, Stephanie Wichuk⁴, Pedro Machado⁵, Robert G. Lambert⁶, Ulrich Weber^7,8, Susanne J Pedersen^9,10, Mikkel Østergaard^9,10, Joachim Sieper³, Martin Rudwaleit^3,11, Xenofon Baraliakos¹² and Walter P. Maksymowych¹³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁴Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Centre for Rheumatology Research & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, ⁶Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁷University of Southern Denmark, Odense, Denmark, ⁸Rheumatology, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁹Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark, ¹⁰Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ¹¹Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ¹²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ¹³University of Alberta, Edmonton, AB, Canada
Background/Purpose: The objective of the study was to compare magnetic resonance imaging (MRI) and conventional radiography of the sacroiliac joints (SIJs) for detection of structural…
Abstract Number: 1147 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany.…
Abstract Number: 1654 • 2018 ACR/ARHP Annual Meeting
Improvement of Cytological Grade and Tear Production in Ankylosing Spondylitis Patients Under Anti-TNF Therapy: A Long-Term Follow-up
Fany Usuba¹, Carla GS Saad², Priscila Novaes¹, Ruth Santo¹, Julio CB Moraes², Eloisa Bonfa³ and Milton Alves⁴, ¹Ophtalmology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Ophtalmolgy Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Clinical expression and pathophysiology of dry eye disease (DED) have recently changed and pro-inflammatory cytokines, such as TNF-α, may play a role in the…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Mikhail Protopopov¹, Fabian Proft¹, Alexandre Sepriano^2,3, Robert B.M. Landewé^4,5, Désirée van der Heijde², Joachim Sieper¹, Martin Rudwaleit^6,7 and Denis Poddubnyy^1,8, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ⁴Zuyderland Medical Center, Heerlen, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, ⁸German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
Abstract Number: 1189 • 2018 ACR/ARHP Annual Meeting
Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
Dam Kim¹, Hyojin Kim², Seongha Cho² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Patient Access Team, Novartis Korea, Seoul, Korea, Republic of (South)
Secukinumab versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean PerspectiveDam Kim1, Hyojin Kim2, SeongHa Cho2, Min-Chan Park11Division of…
Abstract Number: 1830 • 2018 ACR/ARHP Annual Meeting
Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis
Yukiko Maeda¹, Jozsef Karman² and Ellen M. Gravallese³, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Abbvie Bioresearch Center, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) is common, with a prevalence of ~1% in the United States. Patients with SpA suffer from pain and disability due to inflammation…
Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 670 • 2018 ACR/ARHP Annual Meeting
Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
Jürgen Braun¹, Hildrun Haibel², Manouk de Hooge³, Robert B.M. Landewé⁴, Martin Rudwaleit⁵, Todd Fox⁶, Aimee Readie⁷, Hanno Richards⁶, Brian Porter⁸, Ruvie Martin⁷, Denis Poddubnyy⁹, Joachim Sieper¹⁰ and Désirée van der Heijde¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Charité Universitätmedizin Berlin, Berlin, Germany, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Maastricht Univ Medical Center, Maastricht, Netherlands, ⁵Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Charité Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Charité Universitätsmeidzin Berlin, Berlin, Germany, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes IL-17A, improved signs and symptoms of ankylosing spondylitis (AS) in patients (pts) in the MEASURE 1…
Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Konstantinos Thomas¹, Anastasia Makris¹, Christina Tsalapaki¹, Argyro Lazarini¹, Kalliopi Klavdianou¹, Katerina Antonatou¹, Christos Koutsianas¹, Chrisoula Hatzara¹, Emilia Hadziyannis¹ and Dimitrios Vassilopoulos², ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
Abstract Number: 1831 • 2018 ACR/ARHP Annual Meeting
Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity
Zaied Ahmed Bhuyan¹, M. Arifur Rahman², Muralidhara Maradana¹, Ahmed Mehdi³, Giuliana Guggino⁴, Paul Leo⁵, Linda Rehaume¹, Matthew Brown⁵, Francesco Ciccia⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Brisbane, Australia, ²Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ³Diamantina Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Rheumatology Unit, University of Palermo, Palermo, Italy, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia
Background/Purpose: Loss of function RUNX3 variants are associated with ankylosing spondylitis (AS) risk but the mechanism is unknown. Disturbances in immune regulation, intestinal microbial dysbiosis…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.